Elanco Animal Health Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Elanco is a global animal-health company operating as one reportable segment, serving pet and farm-animal markets in more than 90 countries. This unaudited filing covers the three months ended March 31, 2024; comparisons are with Q1 2023. Management cautions that interim results, including seasonal pet-health sales, are not necessarily indicative of full-year results.
Key financial results
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Revenue | $1.205 billion | $1.257 billion | Down 4%; down 4% at constant currency |
| Gross profit / margin | $690 million / 57.3% | $763 million / 60.7% | Margin fell about 3.4 percentage points |
| Operating expenses disclosed | R&D $87 million; marketing, selling and administrative $337 million; amortization $133 million; special charges $46 million | $81 million; $327 million; $134 million; $40 million | R&D and commercial expenses increased |
| Income before taxes | $12 million | $108 million | Down 89% |
| Income tax benefit (expense) | $20 million benefit | $5 million expense | 2024 benefit included a partial valuation-allowance release tied to the aqua sale and state tax credits |
| Net income / diluted EPS | $32 million / $0.06 | $103 million / $0.21 | Net income down 69% |
| Operating cash flow | $2 million | $(145) million | Improved $147 million, primarily from changes in operating assets and liabilities |
| Cash and cash equivalents | $345 million | $352 million at Dec. 31, 2023 | Quarter-end balance |
| Debt | $5.765 billion carrying amount, including current portion | $5.774 billion at Dec. 31, 2023 | About 78% of long-term indebtedness fixed-rate, including swaps; covenants met |
Cash flow from investing was $37 million, including $66 million received on the prior Shawnee and Speke facility divestiture. Cash used in financing was $27 million. The quarter-end cash decrease was $7 million. Available borrowing capacity was approximately $550 million on the revolver and $114 million on the securitization facility.
Material changes versus Q1 2023
- Pet-health revenue decreased 5% to $639 million, reflecting lower volume, partly offset by 3% pricing growth. Farm-animal revenue decreased 3% to $556 million. Contract manufacturing revenue was $10 million, up 11%.
- Management says Q1 2023 revenue benefited from customer purchases shifted ahead of April 2023 ERP-related shipping blackouts: an estimated $90–$110 million overall, including $65–$80 million in pet health and $25–$30 million in farm animal. This is a principal contributor to the year-over-year volume decline.
- Cost of sales rose 4% to $515 million and increased to 43% of revenue from 39%. The company cited inflation, less favorable product mix versus the prior-year period, and reduced manufacturing throughput intended to lower inventory and improve cash conversion.
- Q1 2024 included $39 million of restructuring charges and $7 million of acquisition- and divestiture-related costs; Q1 2023 special charges were $40 million, primarily Bayer integration costs.
- Comprehensive loss was $167 million versus comprehensive income of $185 million, primarily reflecting a $227 million foreign-currency translation loss, partly offset by hedge-related gains.
Outlook, management commentary, risks and contingencies
- Aqua divestiture: Elanco agreed to sell its aqua business to a Merck Animal Health subsidiary for approximately $1.3 billion in cash, subject to customary conditions and regulatory and antitrust approvals; closing was anticipated around mid-2024. The company expects a pretax gain of $600–$650 million and related income tax expense of $170–$190 million. It intends to use after-tax proceeds to repay debt and reduce leverage and interest expense. A $55 million termination fee may apply if the agreement ends because required approvals are not obtained, subject to conditions.
- Restructuring: The February 2024 plan is expected to incur $50–$55 million of pretax charges in 2024, eliminate approximately 420 positions, and generate annualized net savings of $30–$35 million. The plan shifts international resources from farm animal to pet health and changes operations in Argentina, among other markets.
- Operating environment: Management expects global macroeconomic pressures to continue during 2024, citing supply-chain disruption, higher interest rates, foreign-exchange volatility, inflation and variable consumer behavior. It also cited a slow start to the U.S. parasiticide season, competitive pressure in the U.S. veterinary channel, and weakness in China swine markets.
- Debt and interest: The $750 million revolver matures in August 2025; $200 million was outstanding at quarter-end. The $300 million securitization facility matures in July 2026, with $125 million outstanding. Senior notes due 2028 carried a 6.650% interest rate at March 31, 2024. The company’s weighted-average effective interest rate on outstanding indebtedness was 6.40% after swaps.
- Legal matters: Elanco accrued $15 million for a possible SEC resolution concerning pre-mid-2020 channel inventory and sales disclosures, including a $2.5 million increase during Q1; resolution and terms remain uncertain. A $15 million Seresto class-action settlement provision remained recorded, with final court approval scheduled for December 2024 and payment anticipated in Q1 2025 if approved. Other disclosed litigation includes shareholder suits and the Tevra antitrust matter; the filing says material liabilities were not established for the other matters discussed.
- Other commitments and risks: A planned Indianapolis headquarters lease is estimated at $378 million of minimum payments over 25 years, with commencement expected in 2025; final payments may vary. Principal risks include competition, product and regulatory outcomes, reliance on key products, foreign-exchange movements, substantial indebtedness, manufacturing and supply issues, litigation, and execution of the aqua divestiture and restructuring.
Most important facts for investors to verify
- Whether the aqua sale closes on anticipated terms and timing, and the resulting net proceeds, gain, taxes and debt reduction.
- How much of the reported revenue decline reflects the unusual Q1 2023 ERP-related purchasing shift versus current underlying demand, and whether pet-health and farm-animal volumes stabilize.
- Whether gross-margin pressure eases as inventory and manufacturing throughput normalize, and whether the restructuring delivers its projected costs and savings.
- Operating cash generation, working-capital movements, debt maturities, interest costs and covenant headroom given the company’s substantial leverage.
- Developments in the SEC matter, Seresto settlement approval, and other litigation or regulatory contingencies.